| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A658822-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $70.90 |
| Specifications & Purity | ≥99% |
|---|---|
| Storage Temp | Protected from light,Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes . Appearance:Solid IC50& Target:Neuropilin-1 In Vitro:ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1 by 82% at 100 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo:ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes. ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) i Biological Activity:ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. |
| Canonical SMILES | O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](C)N.OC(C(F)(F)F)=O |
|---|---|
| Molecular Weight | 954 |
Enter Lot Number to search for COA:
| Solubility | H2O : ≥ 50 mg/mL (52.41 mM) |
|---|
